Abbott Launches Freenome’s Colorectal Cancer Screening Test

Abbott Labs launches blood test to screen for colorectal cancer

Abbott Laboratories’ cancer diagnostic wing, formerly Madison-based Exact Sciences, is launching a blood test to screen for colorectal cancer.

Abbott launches Freenome’s colorectal cancer screening test

Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences.

Abbott Launches SimpleScreen CRC Blood Test for Colorectal Cancer Screening

Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in average-risk adults, reporting 81.1% sensitivity and 90.4% specificity in a 48,000-patient study.

Abbott unveils SimpleScreen CRC blood test, joining Cologuard Plus in its colorectal cancer screening portfolio

SimpleScreen CRC expands screening options for adults age 45 and older, providing another way to help reach people who otherwise may remain unscreened.